Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-03-04
2008-03-04
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S186000, C548S108000
Reexamination Certificate
active
10627519
ABSTRACT:
Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit.The invention relates to a composition (A), obtained by reacting a compound of the general formula (I)in-line-formulae description="In-line Formulae" end="lead"?M3−n−p−2pr[RuX6−n−p−q−2rBn(H2O)p(OH)q(O)r]2r+1 (I)in-line-formulae description="In-line Formulae" end="tail"?with a compound of the general formula (II)in-line-formulae description="In-line Formulae" end="lead"?B′(HX′)S. (II)in-line-formulae description="In-line Formulae" end="tail"?Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III)in-line-formulae description="In-line Formulae" end="lead"?(B′H)3−n−p−2pr[RuX6−n−p−q−2rBn(H2O)p(OH)q(O)r]2r+1 (III)in-line-formulae description="In-line Formulae" end="tail"?with a compound of the general formula (IV)in-line-formulae description="In-line Formulae" end="lead"?MX′. (IV)in-line-formulae description="In-line Formulae" end="tail"?
REFERENCES:
patent: 4843069 (1989-06-01), Keller et al.
patent: WO97/36595 (1997-10-01), None
Keller et al., European Journal of Inorganic Chemistry (1999), (9), 1551-1555.
F.T. Garzon et al., “Comparative antitumor activity of ruthenium derivatives with 5′-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats”,Cancer Chemother Pharmacol, pp. 347-349, (1987).
B.K. Keppler et al., “New Ruthenium Complexes for the Treatment of Cancer”,Progress in Clinical Biochemistry and Medicine, vol. 10, pp. 41-69, (1989).
H. Depenbrock et al., “Preclinical Activity of Trans-indazolium [Tetrachlorobisindazoleruthenate (III)] (NSC 666158; IndCR; KP 1019) Against Tumour Colony-forming Units and Haematopoietic Progenitor Cells”,European Journal of Cancer, vol. 33, No. 14, pp. 2404-2410, (1997).
A.Galeano et al., “Antitumor Activity of Some Ruthenium Derivatives in Human Colon Cancer Cell Lines in vitro”,Arzneim.-Forsch./Drug Res., 42, vol. 1, No. 6, pp. 821-824, (1992).
F. Kratz et al., “Protein-Binding Properties Of Two Antitumour Ru(III) Complexes To Human Apotransferrin And Apolactoferrin”,Metal-Based Drugs, vol. 1, Nos. 2-3, pp. 169-173 (1994).
F. Kratz et al., “Comparison Of The Antiproliferative Activity Of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin And Transferrin-Bound Forms In A Human Colon Cancer Cell Line”,Metal-Based Drugs, vol. 3, No. 1, pp. 15-23, (1996).
Y.N. Vashisht Gopal et al., “Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium”,J. Biosci, vol. 26, No. 2, pp. 271-276, (2001).
Ernst D. Kreuser et al., “Synergistic Antitumor Interactions Between Newly Synthesized Ruthenium Complexes and Cytokines in Human Colon Carcinoma Cell Lines”,Seminars in Oncology, vol. 19, No. 2 Suppl 3, pp. 73-81, (1992).
S. Pacor et al., “Antitumor action of mer-trichlorobis (dimethylsulphoxide) aminoruthenium (III) (BBR2382) in mice bearing lewis lung carcinoma”,Metal Ions in Biology and Medicine, pp. 482-484, (1990).
F. Kralik et al., “Complex compounds of trivalent ruthenium with pyrazol and imidazol”,Collection Czechoslov. Chem. Commun., vol. 26, pp. 1298-1304, (1961).
B.K. Keppler et al., “Synthesis Molecular Structure, and Tumor-Inhibiting Properties of Imidazolium trans-Bis(imidazole)tetrachlororuthenate(III) and Its Methyl-Substituted Derivatives”,Inorg. Chem., vol. 26, pp. 4366-4370, (1987).
Martin R. Berger et al., “Efficacy of New Ruthenium Complexes against Chemically Induced Autochthonous Colorectal Carcinoma in Rats*”,Anticancer Res., vol. 9, pp. 761-766, (1989).
E. Alessio et al., “Carbonyl Derivatives of Chloride-Dimethyl Sulfoxide-Ruthenium(II) Complexes: Systhesis, Structural Characterization, and Reactivity of Ru(CO)x(DMSO)4-xC12Complexes (x= 1-3)”,Inorg. Chem., vol. 34, pp. 4722-4734, (1995).
Wolfgang Peti et al., “Synthesis of Tumor-Inhibiting Complex Salts Containing the Anion trans-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenylphosphonium Salt”,Eur. J. Inorg. Chem., pp. 1551-1555, (1999).
B.K. Keppler et al., “New Tumor-Inhibiting Metal Complexes. Chemistry and Antitumor Properties”,Met-Based Drugs, vol. 1, Nos. 2-3, pp. 145-150, (1994).
Matthias H. Seelig et al., “Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats”,J. Cancer Res. Clin. Oncol., vol. 118, No. 3, pp. 195-200, (1992).
Michael J. Clark, “The Potential of Ruthenium in Anticancer Pharmaceuticals”,American Chemical Society Symp. Ser., pp. 157-180 (1980).
Djinovic, V., et al., “Novel ruthenium complex K2[Ru(dmgly)C14].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes,” J. Inorg. Biochem., 98(12):2168-73 (Dec. 2004) (Abstract Only).
Van Rensburg, C.E., et al., “Cytotoxicity of a series of water-soluble mixed valent diruthenium tetracarboxylates,” Anticancer Res., 22(2A):889-92 (Mar.-Apr. 2002) (Abstract Only).
Heffeter, P., et al., “Intrinsic and Acquired Forms of Resistance against the Anticancer ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A),” The Journal of Pharmacology and Experimental Therapeutics, 312(1):281-289 (2005).
Gaiddon, C., et al., “Ruthenium (II)-Derived Organometallic Compounds Induce Cytostatic and Cytotoxic Effects on Mammalian Cancer Cell Lines through p53-Dependent and p53-Independent Mechanisms,” The Journal of Pharmacology and Experimental Therapeutics, 315(3):1403-1411 (2005).
Faustus Forschungs Cie. Translational Cancer Research GmbH
McKane Joseph K.
Perkins Coie LLP
Shiao Rei-Tsang
Zhu James J.
LandOfFree
Compositions containing a ruthenium(III) complex and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions containing a ruthenium(III) complex and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions containing a ruthenium(III) complex and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3921299